News - Tradjenta


Current filters:


Popular Filters

Type 2 diabetes market to reach $38.8 billion by 2019


The global type 2 diabetes market is expected to expand from $20.4 billion in 2012 to $38.8 billion by…

Boehringer IngelheimDiabetesEli LillyEuropeGemigliptinMarkets & MarketingNesinaNorth AmericaPharmaceuticalTakeda PharmaceuticalsTradjenta

Positive Ph III data for Trajenta in elderly type 2 diabetes patients


Elderly people with type 2 diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4)…

Boehringer IngelheimDiabetesEli LillyPharmaceuticalResearchTradjentaTrajenta

FDA approves Boehringer and Lilly's Tradjenta and Jentadueto labeling to reflect pancreatitis risk


German family-owned Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) revealed yesterday (June…

Boehringer IngelheimDiabetesEli LillyJentaduetoNorth AmericaPharmaceuticalRegulationTradjenta

FDA approves expanded use of Boehringer and Lilly's Tradjenta


German family-owned drug major Boehringer Ingelheim and US partner and Eli Lilly (NYSE: LLY) said on…

Boehringer IngelheimDiabetesEli LillyNorth AmericaPharmaceuticalRegulationTradjenta

Highlights of American Diabetes Association meeting


The weekend saw a flood of new data on diabetes drug candidates and currently approved treatments presented…

Boehringer IngelheimDegludecDiabetesEli LillyempagliflozinLyxumiaNovo NordiskPharmaceuticalResearchSanofiTradjentaVictoza

Boehringer/Lilly’s linagliptin demonstrates durable efficacy over two years


Results of a 102 week Phase III study for linagliptin (trade named Trajenta in Europe and Tradjenta in…

Boehringer IngelheimDiabetesEli LillyPharmaceuticalResearchTradjentaTrajenta

Boehringer and Lilly’s Trajenta approved for type 2 diabetes in Europe


Following a positive European Medicines Agency advisory committee recommendation two is months ago, Independent…

Boehringer IngelheimDiabetesEli LillyEuropePharmaceuticalRegulationTradjentaTrajenta

Back to top